Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

H. Matsui, A. Takeshita, K. Naito, K. Shinjo, K. Shigeno, M. Maekawa, Y. Yamakawa, M. Tanimoto, M. Kobayashi, K. Ohnishi, R. Ohno

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Gemtuzumab ozogamicin (CMA-676), a calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, has recently been introduced clinically as a promising drug for the treatment of patients with acute myeloid leukemia (AML), more than 90% of which express CD33 antigen. However, our recent study suggested that CMA-676 was excreted by a multi-drug-resistance (MDR) mechanism in P-glycoprotein (P-gp)-expressing leukemia cell lines. We analyzed the in vitro effects of CMA-676 on leukemia cells from 27 AML patients in relation to the amount of P-gp, MDR-associated protein 1 (MRP1), CD33 and CD34, using a multi-laser-equipped flow cytometer. The cytocidal effect of CMA-676, estimated by the amount of hypodiploid portion on cell cycle, was inversely related to the amount of P-gp estimated by MRK16 monoclonal antibody (P = 0.004), and to the P-gp function assessed by intracellular rhodamine-123 accumulation in the presence of PSC833 or MS209 as a MDR modifier (P = 0.0004 and P = 0.002, respectively). In addition, these MDR modifiers reversed CMA-676 resistance in P-gp-expressing CD33+ leukemia cells (P = 0.001 with PSC833 and P = 0.0007 with MS209). In CD33+ AML cells from 13 patients, CMA-676 was less effective on CD33+CD34+ than CD33+CD34- cells (P = 0.002). PSC833 partially restored the effect of CMA-676 in CD33+CD34+ cells. These results suggest that the combined use of CMA-676 and a MDR modifier will be more effective on CD33+ AML with P-gp-related MDR.

Original languageEnglish
Pages (from-to)813-819
Number of pages7
JournalLeukemia
Volume16
Issue number5
DOIs
Publication statusPublished - 2002

Fingerprint

Multiple Drug Resistance
P-Glycoprotein
Leukemia
Acute Myeloid Leukemia
Sialic Acid Binding Ig-like Lectin 3
Monoclonal Antibodies
Rhodamine 123
gemtuzumab
Myeloid Cells
Cell Cycle
Lasers
Cell Line

Keywords

  • Antibody-targeted therapy
  • CD33
  • CD34
  • Gemtuzumab ozogamicin (CMA-676)
  • MDR modifier
  • P-glycoprotein

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. / Matsui, H.; Takeshita, A.; Naito, K.; Shinjo, K.; Shigeno, K.; Maekawa, M.; Yamakawa, Y.; Tanimoto, M.; Kobayashi, M.; Ohnishi, K.; Ohno, R.

In: Leukemia, Vol. 16, No. 5, 2002, p. 813-819.

Research output: Contribution to journalArticle

Matsui, H, Takeshita, A, Naito, K, Shinjo, K, Shigeno, K, Maekawa, M, Yamakawa, Y, Tanimoto, M, Kobayashi, M, Ohnishi, K & Ohno, R 2002, 'Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers', Leukemia, vol. 16, no. 5, pp. 813-819. https://doi.org/10.1038/sj.leu.2402459
Matsui, H. ; Takeshita, A. ; Naito, K. ; Shinjo, K. ; Shigeno, K. ; Maekawa, M. ; Yamakawa, Y. ; Tanimoto, M. ; Kobayashi, M. ; Ohnishi, K. ; Ohno, R. / Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. In: Leukemia. 2002 ; Vol. 16, No. 5. pp. 813-819.
@article{90ca0648f56544b8a3d26948b7b9d81e,
title = "Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers",
abstract = "Gemtuzumab ozogamicin (CMA-676), a calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, has recently been introduced clinically as a promising drug for the treatment of patients with acute myeloid leukemia (AML), more than 90{\%} of which express CD33 antigen. However, our recent study suggested that CMA-676 was excreted by a multi-drug-resistance (MDR) mechanism in P-glycoprotein (P-gp)-expressing leukemia cell lines. We analyzed the in vitro effects of CMA-676 on leukemia cells from 27 AML patients in relation to the amount of P-gp, MDR-associated protein 1 (MRP1), CD33 and CD34, using a multi-laser-equipped flow cytometer. The cytocidal effect of CMA-676, estimated by the amount of hypodiploid portion on cell cycle, was inversely related to the amount of P-gp estimated by MRK16 monoclonal antibody (P = 0.004), and to the P-gp function assessed by intracellular rhodamine-123 accumulation in the presence of PSC833 or MS209 as a MDR modifier (P = 0.0004 and P = 0.002, respectively). In addition, these MDR modifiers reversed CMA-676 resistance in P-gp-expressing CD33+ leukemia cells (P = 0.001 with PSC833 and P = 0.0007 with MS209). In CD33+ AML cells from 13 patients, CMA-676 was less effective on CD33+CD34+ than CD33+CD34- cells (P = 0.002). PSC833 partially restored the effect of CMA-676 in CD33+CD34+ cells. These results suggest that the combined use of CMA-676 and a MDR modifier will be more effective on CD33+ AML with P-gp-related MDR.",
keywords = "Antibody-targeted therapy, CD33, CD34, Gemtuzumab ozogamicin (CMA-676), MDR modifier, P-glycoprotein",
author = "H. Matsui and A. Takeshita and K. Naito and K. Shinjo and K. Shigeno and M. Maekawa and Y. Yamakawa and M. Tanimoto and M. Kobayashi and K. Ohnishi and R. Ohno",
year = "2002",
doi = "10.1038/sj.leu.2402459",
language = "English",
volume = "16",
pages = "813--819",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

AU - Matsui, H.

AU - Takeshita, A.

AU - Naito, K.

AU - Shinjo, K.

AU - Shigeno, K.

AU - Maekawa, M.

AU - Yamakawa, Y.

AU - Tanimoto, M.

AU - Kobayashi, M.

AU - Ohnishi, K.

AU - Ohno, R.

PY - 2002

Y1 - 2002

N2 - Gemtuzumab ozogamicin (CMA-676), a calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, has recently been introduced clinically as a promising drug for the treatment of patients with acute myeloid leukemia (AML), more than 90% of which express CD33 antigen. However, our recent study suggested that CMA-676 was excreted by a multi-drug-resistance (MDR) mechanism in P-glycoprotein (P-gp)-expressing leukemia cell lines. We analyzed the in vitro effects of CMA-676 on leukemia cells from 27 AML patients in relation to the amount of P-gp, MDR-associated protein 1 (MRP1), CD33 and CD34, using a multi-laser-equipped flow cytometer. The cytocidal effect of CMA-676, estimated by the amount of hypodiploid portion on cell cycle, was inversely related to the amount of P-gp estimated by MRK16 monoclonal antibody (P = 0.004), and to the P-gp function assessed by intracellular rhodamine-123 accumulation in the presence of PSC833 or MS209 as a MDR modifier (P = 0.0004 and P = 0.002, respectively). In addition, these MDR modifiers reversed CMA-676 resistance in P-gp-expressing CD33+ leukemia cells (P = 0.001 with PSC833 and P = 0.0007 with MS209). In CD33+ AML cells from 13 patients, CMA-676 was less effective on CD33+CD34+ than CD33+CD34- cells (P = 0.002). PSC833 partially restored the effect of CMA-676 in CD33+CD34+ cells. These results suggest that the combined use of CMA-676 and a MDR modifier will be more effective on CD33+ AML with P-gp-related MDR.

AB - Gemtuzumab ozogamicin (CMA-676), a calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, has recently been introduced clinically as a promising drug for the treatment of patients with acute myeloid leukemia (AML), more than 90% of which express CD33 antigen. However, our recent study suggested that CMA-676 was excreted by a multi-drug-resistance (MDR) mechanism in P-glycoprotein (P-gp)-expressing leukemia cell lines. We analyzed the in vitro effects of CMA-676 on leukemia cells from 27 AML patients in relation to the amount of P-gp, MDR-associated protein 1 (MRP1), CD33 and CD34, using a multi-laser-equipped flow cytometer. The cytocidal effect of CMA-676, estimated by the amount of hypodiploid portion on cell cycle, was inversely related to the amount of P-gp estimated by MRK16 monoclonal antibody (P = 0.004), and to the P-gp function assessed by intracellular rhodamine-123 accumulation in the presence of PSC833 or MS209 as a MDR modifier (P = 0.0004 and P = 0.002, respectively). In addition, these MDR modifiers reversed CMA-676 resistance in P-gp-expressing CD33+ leukemia cells (P = 0.001 with PSC833 and P = 0.0007 with MS209). In CD33+ AML cells from 13 patients, CMA-676 was less effective on CD33+CD34+ than CD33+CD34- cells (P = 0.002). PSC833 partially restored the effect of CMA-676 in CD33+CD34+ cells. These results suggest that the combined use of CMA-676 and a MDR modifier will be more effective on CD33+ AML with P-gp-related MDR.

KW - Antibody-targeted therapy

KW - CD33

KW - CD34

KW - Gemtuzumab ozogamicin (CMA-676)

KW - MDR modifier

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=18444411317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444411317&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402459

DO - 10.1038/sj.leu.2402459

M3 - Article

C2 - 11986941

AN - SCOPUS:18444411317

VL - 16

SP - 813

EP - 819

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -